Main Products
![CAS：2310299-91-1 Benzenesulfonamide, 5-[(2,4-diamino-5-pyrimidinyl)oxy]-2-methoxy-4-(1-methylethyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)](/uploads/24095/small/cas-2310299-91-13a3ef.png?size=365x0)
![CAS：1012341-50-2 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)aMino)-2-Methylpentanoic Acid](/uploads/24095/small/cas-1012341-50-252289.png?size=365x0)
![CAS：865758-96-9 2-[(6-Chloro-3,4-dihydro-3-Methyl-2,4-dioxo-1(2h)-pyriMidinyl)Methyl]benzonitrile](/uploads/24095/small/cas-865758-96-989f2e.png?size=365x0)
Hangzhou Jeci Biochem Technology Co .,Ltd.
Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients and pharmaceutical intermediates, cooperative R & D, custom manufacturing, sales and service as well as import of pharmaceutical raw materials.
About Us >Why Choose Us
Stand out from the many other companies because we have the following advantages：
About Us >- Advantages of series products: The company independently researches and develops new products with rich product lines, including various pharmaceutical intermediates, common pesticide carriers, certain authorized dangerous goods, etc.
- Advantages of new product development: The company attaches great importance to product research and development, and continuously develops new products. We will develop different plans according to the needs of different customers to meet the needs of customers.
- Tailor-made advantages: using the latest manufacturing process, launch a variety of products, can develop new products according to local conditions and environments
CE
CE
ISO
CE
ISO
ISO
ISO
Latest News
-
GBD 2023 Data Released! Global Health Landscape Undergoes Pivotal ShiftsA comprehensive update on global health trends from 2010 to 2023 reveals key findings f...Read More
-
The IgA Nephropathy Field Is Gaining MomentumFrom November 5 to 9, local time, the 58th American Society of Nephrology (ASN) Kidney ...Read More
-
$9.9 Billion Prostate Cancer Drug Approved（ A Breakthrough in Nuclear Medicine）On November 5 , Novartis announced that its radioligand therapy (RLT) drug Pluvicto (...Read More
-
World's First PROTAC Drug Submission: Targeted Degradation Ushers in A New Era!Recently, Arvinas and Pfizer announced that they have submitted a New Drug Application ...Read More
